GC Medical Science Corporation (KOSDAQ:142280)
South Korea · Delayed Price · Currency is KRW 3,425.00
-35.00 (-1.01%)
At close: Jun 10, 2026
GC Medical Science Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other Revenue | - | - | -0 | - | -0 | - |
| 105,483 | 108,413 | 103,852 | 94,011 | 113,109 | 101,675 | |
Revenue Growth (YoY) | -1.08% | 4.39% | 10.47% | -16.89% | 11.25% | -10.32% |
Cost of Revenue | 91,068 | 93,391 | 89,086 | 80,056 | 100,363 | 100,043 |
Gross Profit | 14,414 | 15,022 | 14,767 | 13,955 | 12,746 | 1,631 |
Selling, General & Admin | 7,803 | 8,053 | 8,080 | 7,708 | 10,051 | 11,399 |
Research & Development | 2,996 | 3,114 | 3,383 | 2,880 | 2,167 | 2,134 |
Amortization of Goodwill & Intangibles | 44.45 | 42.01 | 49.75 | 52.93 | 58.29 | 52.82 |
Other Operating Expenses | 66.74 | 70.82 | 75.96 | 77.02 | 95.84 | 92.43 |
Operating Expenses | 11,731 | 12,135 | 12,506 | 12,683 | 14,554 | 21,795 |
Operating Income | 2,684 | 2,887 | 2,261 | 1,272 | -1,808 | -20,164 |
Interest Expense | -2,750 | -2,740 | -2,824 | -3,309 | -2,875 | -1,172 |
Interest & Investment Income | 43.38 | 42.18 | 158.13 | 273.96 | 394.85 | 26.27 |
Currency Exchange Gain (Loss) | -70.82 | 26.88 | -35.14 | -14.87 | 41.89 | 53.98 |
Other Non Operating Income (Expenses) | 2,811 | 1,723 | 5,215 | 4,050 | 641.81 | 89.11 |
EBT Excluding Unusual Items | 2,717 | 1,939 | 4,774 | 2,272 | -3,605 | -21,167 |
Gain (Loss) on Sale of Investments | 263.56 | 263.56 | -428.89 | -396.55 | 650.69 | 49.98 |
Gain (Loss) on Sale of Assets | 15.45 | -0.34 | -210.98 | -9.99 | 3.55 | 8.38 |
Other Unusual Items | - | -147.67 | -738.52 | - | - | - |
Pretax Income | 2,996 | 2,054 | 3,396 | 1,865 | -2,951 | -21,108 |
Income Tax Expense | -1,412 | -1,407 | -0.51 | -11.34 | 108.07 | 29.84 |
Earnings From Continuing Operations | 4,409 | 3,461 | 3,396 | 1,877 | -3,059 | -21,138 |
Net Income to Company | 4,409 | 3,461 | 3,396 | 1,877 | -3,059 | -21,138 |
Minority Interest in Earnings | 64.01 | 205.23 | 184.63 | -79.45 | -521.86 | -64.04 |
Net Income | 4,473 | 3,666 | 3,581 | 1,797 | -3,581 | -21,202 |
Net Income to Common | 4,473 | 3,666 | 3,581 | 1,797 | -3,581 | -21,202 |
Net Income Growth | 171.78% | 2.38% | 99.25% | - | - | - |
Shares Outstanding (Basic) | 22 | 22 | 21 | 21 | 21 | 21 |
Shares Outstanding (Diluted) | 38 | 27 | 87 | 27 | 21 | 21 |
Shares Change (YoY) | -56.12% | -69.46% | 226.38% | 26.96% | 0.05% | - |
EPS (Basic) | 207.55 | 168.72 | 168.00 | 85.25 | -169.87 | -1006.40 |
EPS (Diluted) | 123.33 | 146.00 | 41.00 | 75.80 | -170.00 | -1006.40 |
EPS Growth | 304.11% | 256.10% | -45.91% | - | - | - |
Free Cash Flow | 3,247 | 2,476 | 445.24 | -1,391 | 7,454 | -21,793 |
Free Cash Flow Per Share | 85.18 | 92.80 | 5.10 | -51.96 | 353.61 | -1034.47 |
Gross Margin | 13.66% | 13.86% | 14.22% | 14.84% | 11.27% | 1.60% |
Operating Margin | 2.54% | 2.66% | 2.18% | 1.35% | -1.60% | -19.83% |
Profit Margin | 4.24% | 3.38% | 3.45% | 1.91% | -3.17% | -20.85% |
Free Cash Flow Margin | 3.08% | 2.28% | 0.43% | -1.48% | 6.59% | -21.43% |
EBITDA | 6,652 | 6,818 | 6,047 | 5,125 | 2,299 | -16,333 |
EBITDA Margin | 6.31% | 6.29% | 5.82% | 5.45% | 2.03% | -16.06% |
D&A For EBITDA | 3,968 | 3,930 | 3,786 | 3,854 | 4,107 | 3,831 |
EBIT | 2,684 | 2,887 | 2,261 | 1,272 | -1,808 | -20,164 |
EBIT Margin | 2.54% | 2.66% | 2.18% | 1.35% | -1.60% | -19.83% |
Advertising Expenses | - | 165.69 | 346.48 | 99.73 | 156.14 | 198.06 |